The pathogenicity and virulence of Leishmania-interplay of virulence factors with host defenses

AK Gupta, S Das, M Kamran, SA Ejazi, N Ali - Virulence, 2022 - Taylor & Francis
Leishmaniasis is a group of disease caused by the intracellular protozoan parasite of the
genus Leishmania. Infection by different species of Leishmania results in various host …

Leishmania Protein Kinases: Important Regulators of the Parasite Life Cycle and Molecular Targets for Treating Leishmaniasis

A Efstathiou, D Smirlis - Microorganisms, 2021 - mdpi.com
Leishmania is a protozoan parasite of the trypanosomatid family, causing a wide range of
diseases with different clinical manifestations including cutaneous, mucocutaneous and …

Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival

N Baker, CMC Catta-Preta, R Neish, J Sadlova… - Nature …, 2021 - nature.com
Differentiation between distinct stages is fundamental for the life cycle of intracellular
protozoan parasites and for transmission between hosts, requiring stringent spatial and …

Emerging therapeutic targets for treatment of leishmaniasis

S Sundar, B Singh - Expert opinion on therapeutic targets, 2018 - Taylor & Francis
Introduction: Parasitic diseases that pose a threat to human life include leishmaniasis–
caused by protozoan parasite Leishmania species. Existing drugs have limitations due to …

Molecular-level strategic goals and repressors in Leishmaniasis–Integrated data to accelerate target-based heterocyclic scaffolds

M Abirami, BK Kumar, S Dey, S Johri… - European Journal of …, 2023 - Elsevier
Leishmaniasis is a complex of neglected tropical diseases caused by various species of
leishmanial parasites that primarily affect the world's poorest people. A limited number of …

Molecular targets and pathways for the treatment of visceral leishmaniasis

V Jain, K Jain - Drug discovery today, 2018 - Elsevier
Highlights•Visceral leishmaniasis is a complicated infectious disease.•Emerging resistance
is one of the main complications in treatment visceral leishmaniasis.•A comprehensive …

Human Aurora kinase inhibitor Hesperadin reveals epistatic interaction between Plasmodium falciparum PfArk1 and PfNek1 kinases

BJ Morahan, C Abrie, K Al-Hasani, MB Batty… - Communications …, 2020 - nature.com
Mitosis has been validated by numerous anti-cancer drugs as being a druggable process,
and selective inhibition of parasite proliferation provides an obvious opportunity for …

Who needs a contractile actomyosin ring? The plethora of alternative ways to divide a protozoan parasite

TC Hammarton - Frontiers in Cellular and Infection Microbiology, 2019 - frontiersin.org
Cytokinesis, or the division of the cytoplasm, following the end of mitosis or meiosis, is
accomplished in animal cells, fungi, and amoebae, by the constriction of an actomyosin …

[HTML][HTML] Cell Death in Leishmania donovani promastigotes in response to Mammalian Aurora Kinase B Inhibitor–Hesperadin

R Chhajer, A Bhattacharyya, N Ali - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Deciphering how hesperadin, a repurposed mammalian aurora kinase B inhibitor, affects
the cellular pathways in Leishmania donovani might be beneficial. This investigation sought …

[HTML][HTML] Unveiling the kinomes of Leishmania infantum and L. braziliensis empowers the discovery of new kinase targets and antileishmanial compounds

JVB Borba, AC Silva, PIP Ramos, N Grazzia… - Computational and …, 2019 - Elsevier
Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania
(NTD) endemic in 98 countries. Although some drugs are available, current treatments deal …